Elevation Oncology 将来の成長

Future 基準チェック /06

Elevation Oncologyの収益は年間16.5%で減少すると予測されていますが、年間収益は年間87%で増加すると予想されています。EPS は年間0.1%で減少すると予想されています。

主要情報

-16.5%

収益成長率

-0.1%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	87.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	07 Nov 2024

今後の成長に関する最新情報

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

業績と収益の成長予測

NasdaqGS:ELEV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-88	-93	-117	5
12/31/2025	N/A	-63	-81	-53	7
12/31/2024	N/A	-48	-42	-39	7
9/30/2024	N/A	-42	-38	-38	N/A
6/30/2024	N/A	-40	-43	-43	N/A
3/31/2024	N/A	-39	-49	-49	N/A
12/31/2023	N/A	-46	-56	-56	N/A
9/30/2023	N/A	-57	-62	-62	N/A
6/30/2023	N/A	-85	-93	-93	N/A
3/31/2023	N/A	-95	-88	-88	N/A
12/31/2022	N/A	-95	-86	-85	N/A
9/30/2022	N/A	-86	-77	-77	N/A
6/30/2022	N/A	-59	-40	-40	N/A
3/31/2022	N/A	-44	-35	-35	N/A
12/31/2021	N/A	-32	-30	-30	N/A
9/30/2021	N/A	-31	-25	-25	N/A
6/30/2021	N/A	-22	-22	-21	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-17	-12	-12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ELEV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ELEV今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ELEV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ELEV来年は収益がないと予測されています。

高い収益成長: ELEV来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ELEVの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Elevation Oncology 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 8.2% to US$7.50

Price target increased by 24% to US$6.00

Price target decreased by 19% to US$4.17

Price target decreased to US$5.17

Recent updates

Price target decreased by 8.2% to US$7.50

Elevation Oncology Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirement

New minor risk - Market cap size

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Elevation Oncology, Inc. has completed an IPO in the amount of $100 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘